MS41 is a highly potent and selective PROTAC degrader of eleven-nineteen leukemia (ENL) that recruits the von Hippel–Lindau (VHL) E3 ubiquitin ligase, with DC50 values of 3.50 nM (MV4;11), 2.84 nM (SEMK2), 3.03 nM (Jurkat), and 26.58 nM (KASUMI1). It suppresses oncogenic gene expression, inhibits leukemia cell proliferation, and reduces MLL-r leukemia progression in a […]

MS41 is a highly potent and selective PROTAC degrader of eleven-nineteen leukemia (ENL) that recruits the von Hippel–Lindau (VHL) E3 ubiquitin ligase, with DC50 values of 3.50 nM (MV4;11), 2.84 nM (SEMK2), 3.03 nM (Jurkat), and 26.58 nM (KASUMI1). It suppresses oncogenic gene expression, inhibits leukemia cell proliferation, and reduces MLL-r leukemia progression in a […]

MS41 is a highly potent and selective PROTAC degrader of eleven-nineteen leukemia (ENL) that recruits the von Hippel–Lindau (VHL) E3 ubiquitin ligase, with DC50 values of 3.50 nM (MV4;11), 2.84 nM (SEMK2), 3.03 nM (Jurkat), and 26.58 nM (KASUMI1). It suppresses oncogenic gene expression, inhibits leukemia cell proliferation, and reduces MLL-r leukemia progression in a […]

MCB-22-174 is a potent agonist of Piezo1, with an EC50 value of 6.28 µM. It activates the Ca2+-related extracellular signal-related kinases and calcium–calmodulin (CaM)-dependent protein kinase II (CaMKII) pathway and promotes mesenchymal stem cells osteoblastic differentiation, exhibiting its potential use in research for the treatment of disuse osteoporosis (OP).

MCB-22-174 is a potent agonist of Piezo1, with an EC50 value of 6.28 µM. It activates the Ca2+-related extracellular signal-related kinases and calcium–calmodulin (CaM)-dependent protein kinase II (CaMKII) pathway and promotes mesenchymal stem cells osteoblastic differentiation, exhibiting its potential use in research for the treatment of disuse osteoporosis (OP).

MCB-22-174 is a potent agonist of Piezo1, with an EC50 value of 6.28 µM. It activates the Ca2+-related extracellular signal-related kinases and calcium–calmodulin (CaM)-dependent protein kinase II (CaMKII) pathway and promotes mesenchymal stem cells osteoblastic differentiation, exhibiting its potential use in research for the treatment of disuse osteoporosis (OP).